GB9424708D0 - Use of inflammatory modulators in the treatment of chronic or recalcitrant skin damage - Google Patents

Use of inflammatory modulators in the treatment of chronic or recalcitrant skin damage

Info

Publication number
GB9424708D0
GB9424708D0 GB9424708A GB9424708A GB9424708D0 GB 9424708 D0 GB9424708 D0 GB 9424708D0 GB 9424708 A GB9424708 A GB 9424708A GB 9424708 A GB9424708 A GB 9424708A GB 9424708 D0 GB9424708 D0 GB 9424708D0
Authority
GB
United Kingdom
Prior art keywords
chronic
treatment
skin damage
inflammatory modulators
recalcitrant skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB9424708A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to GB9424708A priority Critical patent/GB9424708D0/en
Publication of GB9424708D0 publication Critical patent/GB9424708D0/en
Priority to AU41771/96A priority patent/AU4177196A/en
Priority to PCT/EP1995/004715 priority patent/WO1996017606A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB9424708A 1994-12-07 1994-12-07 Use of inflammatory modulators in the treatment of chronic or recalcitrant skin damage Pending GB9424708D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB9424708A GB9424708D0 (en) 1994-12-07 1994-12-07 Use of inflammatory modulators in the treatment of chronic or recalcitrant skin damage
AU41771/96A AU4177196A (en) 1994-12-07 1995-11-28 Use of inflammatory modulators in the treatment of chronic or recalcitrant skin damage
PCT/EP1995/004715 WO1996017606A1 (en) 1994-12-07 1995-11-28 Use of inflammatory modulators in the treatment of chronic or recalcitrant skin damage

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9424708A GB9424708D0 (en) 1994-12-07 1994-12-07 Use of inflammatory modulators in the treatment of chronic or recalcitrant skin damage

Publications (1)

Publication Number Publication Date
GB9424708D0 true GB9424708D0 (en) 1995-02-01

Family

ID=10765563

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9424708A Pending GB9424708D0 (en) 1994-12-07 1994-12-07 Use of inflammatory modulators in the treatment of chronic or recalcitrant skin damage

Country Status (3)

Country Link
AU (1) AU4177196A (en)
GB (1) GB9424708D0 (en)
WO (1) WO1996017606A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002241282A (en) * 1996-05-21 2002-08-28 Bayer Yakuhin Ltd Medicine for treating allergic dermatitis
EP1283199A4 (en) * 2000-05-16 2003-12-17 Takeda Chemical Industries Ltd Melanin-concentrating hormone antagonist
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5798209A (en) * 1980-12-09 1982-06-18 Kowa Co Remedy for dermatopathy for external use
US4925873A (en) * 1988-09-01 1990-05-15 E. R. Squibb & Sons, Inc. Method of treating skin injuries using thromboxane A2 receptor antagonists

Also Published As

Publication number Publication date
WO1996017606A1 (en) 1996-06-13
AU4177196A (en) 1996-06-26

Similar Documents

Publication Publication Date Title
GB9401176D0 (en) Device for preventing or reducing the incidence or intensity of pain in the body
CY2508B1 (en) Benzopyrans and their use as therapeutic agents
ZA953256B (en) Skin treatment composition
EP0691112A3 (en) Ophthalmic treatment apparatus and its use
AU2466695A (en) The use of famotidine and related compounds in the treatment of movement disorders
GB9323044D0 (en) In or relating to the treatment of effluents
GB2314273B (en) The use of TCET in the prophylaxis and treatment of allergies
ZA951088B (en) Use of substituted arylcyclobutylalkylamine compounds in the treatment of seizures neurological disorders and neurological damage
GB9424708D0 (en) Use of inflammatory modulators in the treatment of chronic or recalcitrant skin damage
IL115505A0 (en) Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
GB9405021D0 (en) Skin treatment composition
GB9211736D0 (en) Allergic treatment
AU2705495A (en) Use of rooperol and hypoxoside and their derivatives in the treatment of inflammatory
IL127350A0 (en) Combinations comprising VX478 zidovudine and/or 1592U89 for use in the treatment of HIV
EP0893123A4 (en) Agent for use in the prevention and treatment of disorders associated with various types of ageing
GB2275191B (en) Use of antifungal compounds in the treatment of skin disorders
SG47098A1 (en) Diamines in the treatment of arrhythmia
ZA952120B (en) Skin treatment composition
AU5374898A (en) The use of oxandrolone in the treatment of chronic fatigue syndrome
GB9603657D0 (en) Improvements in the treatment of vaginal infections
ZA9810815B (en) Use of lectin preparations in the treatment of bladder carcinoma
GB2296238B (en) Improvements in or relating to effluent treatment
AUPP715198A0 (en) The use of banana components in the treatment of various skin conditions
ZA954732B (en) Benzopyrans and their use as therapeutic agents
GB9402103D0 (en) Surface treatment